Li C, Zhou L, Yin X
Front Pharmacol. 2024; 15:1342181.
PMID: 38500764
PMC: 10944884.
DOI: 10.3389/fphar.2024.1342181.
Estevao D, da Cruz-Ribeiro M, Cardoso A, Costa A, Oliveira M, Duarte T
Cell Oncol (Dordr). 2023; 46(6):1545-1558.
PMID: 37273145
PMC: 10698107.
DOI: 10.1007/s13402-023-00828-3.
Huang L, Li W, Lu Y, Ju Q, Ouyang M
Front Oncol. 2023; 13:1098501.
PMID: 36910614
PMC: 9992732.
DOI: 10.3389/fonc.2023.1098501.
Benjamin-Rivera J, Cardona-Rivera A, Vazquez-Maldonado A, Dones-Lassalle C, Pabon-Colon H, Rodriguez-Rivera H
Inorganics (Basel). 2023; 8(9).
PMID: 36844373
PMC: 9957567.
DOI: 10.3390/inorganics8090048.
Zhang X, Zhou Y, Xu S, Xu S, Xiong Y, Xu K
Microbiol Spectr. 2023; 11(1):e0190622.
PMID: 36625575
PMC: 9927099.
DOI: 10.1128/spectrum.01906-22.
CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research.
Liu H, Yuan M, Mitra R, Zhou X, Long M, Lei W
Genome Med. 2022; 14(1):118.
PMID: 36229842
PMC: 9563764.
DOI: 10.1186/s13073-022-01119-6.
Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach.
Islam S, Hoque N, Nasrin N, Hossain M, Rizwan F, Biswas K
Life (Basel). 2022; 12(7).
PMID: 35888054
PMC: 9317809.
DOI: 10.3390/life12070963.
Supplementation with High or Low Iron Reduces Colitis Severity in an AOM/DSS Mouse Model.
Moon S, Kim M, Kim Y, Lee S
Nutrients. 2022; 14(10).
PMID: 35631174
PMC: 9147005.
DOI: 10.3390/nu14102033.
Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.
Bakrania A, Zheng G, Bhat M
Pharmaceutics. 2022; 14(1).
PMID: 35056937
PMC: 8779722.
DOI: 10.3390/pharmaceutics14010041.
A DNA Aptameric Ligand of Human Transferrin Receptor Generated by Cell-SELEX.
Zhang N, Bing T, Shen L, Feng L, Liu X, Shangguan D
Int J Mol Sci. 2021; 22(16).
PMID: 34445629
PMC: 8396340.
DOI: 10.3390/ijms22168923.
Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.
Ginghina O, Hudita A, Zaharia C, Tsatsakis A, Mezhuev Y, Costache M
Materials (Basel). 2021; 14(9).
PMID: 34066710
PMC: 8125868.
DOI: 10.3390/ma14092440.
Engineered Human Heavy-Chain Ferritin with Half-Life Extension and Tumor Targeting by PAS and RGDK Peptide Functionalization.
Yin S, Wang Y, Zhang B, Qu Y, Liu Y, Dai S
Pharmaceutics. 2021; 13(4).
PMID: 33918853
PMC: 8070472.
DOI: 10.3390/pharmaceutics13040521.
Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.
Gaur K, Vazquez-Salgado A, Duran-Camacho G, Dominguez-Martinez I, Benjamin-Rivera J, Fernandez-Vega L
Inorganics (Basel). 2021; 6(4).
PMID: 33912613
PMC: 8078164.
DOI: 10.3390/inorganics6040126.
MACC1 regulates clathrin-mediated endocytosis and receptor recycling of transferrin receptor and EGFR in colorectal cancer.
Imbastari F, Dahlmann M, Sporbert A, Mattioli C, Mari T, Scholz F
Cell Mol Life Sci. 2021; 78(7):3525-3542.
PMID: 33469705
PMC: 8038998.
DOI: 10.1007/s00018-020-03734-1.
Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y
Signal Transduct Target Ther. 2020; 5(1):101.
PMID: 32561705
PMC: 7305320.
DOI: 10.1038/s41392-020-0207-x.
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.
Brown R, Richardson K, Kabir T, Trinder D, Ganss R, Leedman P
Front Oncol. 2020; 10:476.
PMID: 32328462
PMC: 7160331.
DOI: 10.3389/fonc.2020.00476.
TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer.
Cheng X, Fan K, Wang L, Ying X, Sanders A, Guo T
Cell Death Dis. 2020; 11(2):92.
PMID: 32024821
PMC: 7002446.
DOI: 10.1038/s41419-020-2272-z.
Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway.
Cui C, Cheng X, Yan L, Ding H, Guan X, Zhang W
Cancer Manag Res. 2019; 11:6323-6341.
PMID: 31372038
PMC: 6628123.
DOI: 10.2147/CMAR.S198911.
Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2.
Miyazawa M, Bogdan A, Tsuji Y
Cell Chem Biol. 2018; 26(1):85-97.e4.
PMID: 30449675
PMC: 6338505.
DOI: 10.1016/j.chembiol.2018.10.009.
Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H, Pandey M, Chin P, Lin Phang Y, Cheah J, Ooi S
Drug Deliv Transl Res. 2018; 8(5):1545-1563.
PMID: 29916012
DOI: 10.1007/s13346-018-0552-2.